Du, Jinyan

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature

Melanoma and MAPK PathwaysCancer Cells and Metastasis

Cited by 1,771

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 1,548

Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 509

Model‐Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers

Kirouac, D., Lahdenranta, J., Du, J., Yarar, D., Onsum, M., Nielsen, U., & McDonagh, C. (2015) · CPT: Pharmacometrics & Systems Pharmacology

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 5